DOI QR코드

DOI QR Code

High Expression Level of Preoperative Serum Uroplakin III is Associated with Biologically Aggressive Bladder Cancer

  • Tsumura, Hideyasu (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) ;
  • Matsumoto, Kazumasa (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) ;
  • Ikeda, Masaomi (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) ;
  • Yanagita, Kengo (Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University) ;
  • Hirano, Shuhei (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) ;
  • Hagiwara, Masahiro (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) ;
  • Nagashio, Ryo (Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University) ;
  • Fujita, Tetsuo (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University) ;
  • Sato, Yuichi (Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University) ;
  • Iwamura, Masatsugu (Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University)
  • Published : 2015.03.09

Abstract

Background: Uroplakins have been widely investigated as potential markers in patients with bladder cancer because these proteins are specific to the urothelium. However, the role of uroplakin proteins in bladder cancer remains unknown. In this study, preoperative serum levels of uroplakin III were measured in patients with urothelial carcinoma of the urinary bladder and examined for possible association with clinicopathological features and clinical outcomes. Materials and Methods: This study included 52 bladder cancer patients at various stages and 28 healthy controls. Uroplakin III levels were detected in preoperative sera using an automated dot blot system and a micro-dot blot array. Results: There was a significant increase in serum uroplakin III levels in patients with bladder cancer as compared to healthy controls (p<0.05). In addition, serum uroplakin III levels were associated with muscle-invasive status, high grade and lymphovascular invasion (p<0.02). Log-rank tests indicated high serum uroplakin III to be significantly associated with cancer-specific mortality. Conclusions: Determination of serum uroplakin III level could be valuable for identifying patients with biologically aggressive bladder cancer.

Keywords

Urothelial carcinoma;bladder;serum marker;protein;uroplakin

Acknowledgement

Supported by : Japan society for promotion of science

References

  1. Bringuier PP, Umbas R, Schaafsma HE, et al (1993). Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res, 53, 3241-5.
  2. El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al (2009). Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol, 19, 1575-81. https://doi.org/10.1007/s00330-009-1340-7
  3. Ghafouri-Fard S, Nekoohesh L, Motevaseli E (2014). Bladder cancer biomarkers: review and update. Asian Pac J Cancer Prev, 15, 2395-403. https://doi.org/10.7314/APJCP.2014.15.6.2395
  4. Griffiths G, Hall R, Sylvester R, et al (2011). International phase III trial assessing neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol, 29, 2171-7. https://doi.org/10.1200/JCO.2010.32.3139
  5. Huang HY, Shariat SF, Sun TT, et al (2007). Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol, 38, 1703-13. https://doi.org/10.1016/j.humpath.2007.04.003
  6. Ikeda M, Matsumoto K, Nishi M, et al (2014). Comparison of radical cystectomy and chemoradiotherapy in patients with locally advanced bladder cancer. Asian Pac J Cancer Prev, 15, 6519-24. https://doi.org/10.7314/APJCP.2014.15.16.6519
  7. Kobayashi M, Matsumoto T, Ryuge S, et al (2012). CAXII Is a sero-diagnostic marker for lung cancer. PLoS One, 7, 33952. https://doi.org/10.1371/journal.pone.0033952
  8. Li SM, Zhang ZT, Chan S, et al (1999). Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol, 162, 931-5. https://doi.org/10.1097/00005392-199909010-00093
  9. Lu JJ, Kakehi Y, Takahashi T, et al (2000). Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res, 6, 3166-71.
  10. Matsumoto K, Satoh T, Irie A, et al (2008). Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology, 72, 444-9. https://doi.org/10.1016/j.urology.2007.11.128
  11. Matsumoto K, Shariat SF, Casella R, et al (2003). Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol, 170, 2248-52. https://doi.org/10.1097/01.ju.0000094189.93805.17
  12. Otunctemur A, Koklu I, Ozbek E, et al (2014). Are bladder neoplasms more aggresive in patients with a smoking-related second malignancy? Asian Pac J Cancer Prev, 15, 4025-8. https://doi.org/10.7314/APJCP.2014.15.9.4025
  13. Schwaibold HE, Sivalingam S, May F, Hartung R (2006). The value of a second transurethral resection for T1 bladder cancer. BJU Int, 97, 1199-201. https://doi.org/10.1111/j.1464-410X.2006.06144.x
  14. Takeuchi M, Sasaki S, Ito M, et al (2009). Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology, 251, 112-21. https://doi.org/10.1148/radiol.2511080873
  15. Wang HF and Wang JS (2012). Research progress in potential urinary markers for the early detection, diagnosis and follow-up of human bladder cancer. Asian Pac J Cancer Prev, 13, 1723-6. https://doi.org/10.7314/APJCP.2012.13.5.1723
  16. Wu XR, Lin JH, Walz T, et al (1994). Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem, 269, 13716-24.
  17. Xu X, Sun TT, Gupta PK, et al (2001). Uroplakin as a marker for typing metastatic transitional cell carcinoma on fine-needle aspiration specimens. Cancer, 93, 216-21. https://doi.org/10.1002/cncr.9032

Cited by

  1. Protein expression profile related to cisplatin resistance in bladder cancer cell lines detected by two-dimensional gel electrophoresis vol.36, pp.4, 2015, https://doi.org/10.2220/biomedres.36.253
  2. Comparative lipidomic study of urothelial cancer models: association with urothelial cancer cell invasiveness vol.12, pp.11, 2016, https://doi.org/10.1039/C6MB00477F
  3. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer vol.18, pp.7, 2018, https://doi.org/10.1080/14737159.2018.1490179
  4. Uroplakin IIIa Is a Marker in Bladder Cancer but Seems Not to Reflect Chemical Carcinogenesis vol.2018, pp.2314-6141, 2018, https://doi.org/10.1155/2018/8315410